Lutetium-177 DOTA girentuximab

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameLutetium-177 DOTA girentuximab
Drug Alias NameLu-177-DOTA-cG250Lu-177-DOTA-girentuximab177Lu-girentuximab177Lu-TLX250TLX-250
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6] 
Mechanisms of ActionIonising radiation emittersCarbonic anhydrase IX inhibitors
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesWilex AGHeidelberg Pharma AGTelix Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLudwig Institute For Cancer Research
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A